You are here

All Licensing Opportunities

CRUK is seeking a partner to collaborate on a proprietary technology better able to identify mutational patterns in cancer genomes for patient stratification.

Patented technology that allows manipulation of the disulfide bond configuration of the hinge/CH1 regions to control the activity of mAbs directed against a range of immune receptors. This permits the fine-tuning of biological function.

We have developed first-in-class IKKα selective compounds with in vivo data showing strong inhibition of tumour growth. We are seeking a licensing/co-development partner to support key biological data and drive candidate selection for clinical and regulatory development.

A large curated and centralized database of mammogram images and associated clinical data from multiple NHS Breast Cancer screening sites.

We are seeking a partner experienced in the field of cell therapy development and in the Chinese regulatory environment to take this technology through to first in man trials in China. The technology demonstrates in vivo efficacy with no observed toxicities. Cancer Research UK is prosecuting a patent for the technology and the relevant sequences.

CRUK is seeking an industry partner for co-development and/or exclusive licensing of its CLEC14A IP, materials and know-how, to progress anti-CLEC14A antibodies into first-in-human clinical studies.

Peptides with excellent affinity and selectivity for ɑvß6 have been identified and characterised.

In vitro and in vivo data demonstrates the potential of these peptides as novel PET and SPECT imaging probes, tumour targeting agents and functional inhibitors of ɑvß6.

 

We are seeking a commercial partner interested in pursuing a co-development or direct licensing arrangement.

Peptides with excellent affinity and selectivity for ɑvß6 have been identified and characterised.

In vitro and in vivo data demonstrates the potential of these peptides as the basis for novel PET and SPECT imaging probes, tumour targeting agents and functional inhibitors of ɑvß6. 

The Tyrer-Cuzick model has been shown in independent studies to be the most consistently accurate when compared with other available breast cancer risk assessment tools. It incorporates family history, endogenous hormonal factors, benign disease, risk factors such as age and body mass index, as well as genetic factors (including BRCA) into a single statistical model. The model has been incorporated into a computer programme, the IBIS software that gives a personalised risk estimate. IBIS is available for non-exclusive licensing for stand-alone use or for incorporation into broader software platforms.

Pages